Compare CTMX & TIPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTMX | TIPT |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.2M | 704.3M |
| IPO Year | 2015 | 2007 |
| Metric | CTMX | TIPT |
|---|---|---|
| Price | $3.89 | $17.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 196.8K |
| Earning Date | 11-06-2025 | 10-31-2025 |
| Dividend Yield | N/A | ★ 1.37% |
| EPS Growth | ★ 50.22 | 17.79 |
| EPS | 0.24 | ★ 1.15 |
| Revenue | $113,631,000.00 | ★ $2,070,076,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.28 | ★ $15.23 |
| Revenue Growth | N/A | ★ 4.25 |
| 52 Week Low | $0.40 | $17.07 |
| 52 Week High | $4.62 | $27.41 |
| Indicator | CTMX | TIPT |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 38.84 |
| Support Level | $3.66 | $17.15 |
| Resistance Level | $4.20 | $18.81 |
| Average True Range (ATR) | 0.24 | 0.48 |
| MACD | -0.04 | -0.09 |
| Stochastic Oscillator | 43.84 | 30.42 |
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.